Kite Pharma Asks FDA to Pave Way Toward It Holding Clinical Trials of Its Myeloma Therapy KITE-585 – Myeloma Research News
Myeloma Research News |
Kite Pharma Asks FDA to Pave Way Toward It Holding Clinical Trials of Its Myeloma Therapy KITE-585
Myeloma Research News Because the protein is crucial to myeloma cells’ survival and growth, it is a good target for chimeric antigen receptor T-cell treatments, also known as CAR T-cell therapies. Those therapies use a patient’s own immune cells to combat their disease. The … Kite Pharma, Inc. (NASDAQ:KITE) Traded 21.0% Above Its 50 Day AverageModern Readers Kite Pharma, Inc. (NASDAQ:KITE) Stock Closed Much Higher Than …HugoPress Kite Pharma, Inc. (NASDAQ:KITE) Traded Significantly Above Its 50 …Highlight Press Finance Daily all 21 news articles » |
STAT |
New CAR–T drug for leukemia, while effective, is ‘going to cost a fortune’
STAT The treatment, CTL019, belongs to a new class of medications called CAR–T cell therapies, which involve harvesting patients’ immune cells and genetically altering them to kill cancer. It’s been tested in patients whose leukemia has relapsed in spite of … |